druglikeness Archive

  • The goal of drug discovery is to find potent and selective inhibitors for particular targets. A good ligand thus should be small (for better bio-availability) and potent. The larger is...

    Does size matter?

    The goal of drug discovery is to find potent and selective inhibitors for particular targets. A good ligand thus should be small (for better bio-availability) and potent. The larger is...

    Continue Reading...

  • It’s “well known” that we all need to find the stronger inhibitors against any specific therapeutic target as possible. The motivation is that the strongest inhibitors are most probably less...

    Do we need those nM-inhibitors?

    It’s “well known” that we all need to find the stronger inhibitors against any specific therapeutic target as possible. The motivation is that the strongest inhibitors are most probably less...

    Continue Reading...

  • We use a few chemical compounds vendors in our drug discovery programs (let us call them “Provider I”, “Provider II”, and “Provider III”). Nowadays chemicals providers normally claim about 1M...

    How drug-like are vendor libraries?

    We use a few chemical compounds vendors in our drug discovery programs (let us call them “Provider I”, “Provider II”, and “Provider III”). Nowadays chemicals providers normally claim about 1M...

    Continue Reading...

  • Druglikeness is a qualitative concept used in drug design for an estimate on how “druglike” a prospective compound is. Usually it is estimated from the molecular structure, often even before...

    Drug likeness: what do bioavailability and toxicity properties tell us about druglikeness?

    Druglikeness is a qualitative concept used in drug design for an estimate on how “druglike” a prospective compound is. Usually it is estimated from the molecular structure, often even before...

    Continue Reading...

Get Adobe Flash playerPlugin by wpburn.com wordpress themes